Roche brings oral therapy to treat Spinal Muscular Atrophy in India

Swiss firm Roche has announced the launch of Evrysdi (risdiplam), the first and only approved treatment in India for a rare disease called Spinal Muscular Atrophy (SMA). Evrysdi was first approved by the US FDA in August 2020 and is available in India within 11 months of US approval. Since its launch, over 4,000 SMA patients across 50+ countries have benefitted from Evrysdi. Evrysdi is administered daily at home orally (it is supplied as a powder which is constituted into a liquid solution and taken once daily by mouth or feeding tube if required) and is designed to treat SMA by increasing production of the Survival Motor Neuron (SMN) protein. It is approved for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older. Evrysdi was approved by Indian health authorities after reviewing its efficacy and safety data from three global clinical studies designed to represent a broad spectrum of people living with SMA.